Baseline characteristics of participants in the JUPITER trial, by study group
| Characteristic | Study group; no. (%) of participants* | |
|---|---|---|
| Rosuvastatin n = 8901 | Placebo n = 8901 | |
| Age, yr | ||
| < 60 | 1846 (20.7) | 1843 (20.7) |
| 60–69 | 4177 (46.9) | 4241 (47.6) |
| ≥ 70 | 2878 (32.3) | 2817 (31.6) |
| Female sex | 3426 (38.5) | 3375 (37.9) |
| Current smoker | 1400 (15.7) | 1420 (16.0) |
| Metabolic syndrome | 3652 (41.0) | 3723 (41.8) |
| Body mass index, kg/m2 | n = 8870 | n = 8878 |
| < 25 | 2040 (23.0) | 2033 (22.9) |
| 25–< 30 | 3495 (39.4) | 3514 (39.6) |
| ≥ 30 | 3338 (37.6) | 3336 (37.6) |
| High-sensitivity C-reactive protein level,† nmol/L, median (IQR) | 40.0 (26.7–67.6) | 41.0 (26.7–68.6) |
| Lipid level, mmol/L, median (IQR) | ||
| LDL cholesterol | 2.79 (2.43–3.08) | 2.79 (2.43–3.08) |
| HDL cholesterol | 1.27 (1.03–1.56) | 1.27 (1.03–1.56) |
| Triglycerides | 1.33 (0.96–1.91) | 1.33 (0.97–1.91) |
| Total cholesterol | 4.81 (4.34–5.17) | 4.78 (4.37–5.15) |
Note: HDL = high-density lipoprotein, IQR = interquartile range, JUPITER = Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin, LDL = low-density lipoprotein.
↵* Unless stated otherwise.
↵† C-reactive protein levels were reported as averages based on levels from two visits before the start of the trial (screening and randomization visits).